Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2025-03-20 00:00:00 ET · period of report 2025-03-18 · accession 0001415889-25-008710 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-20 | 2025-03-18+ | STOK | Ticho Barry | Chief MEDICAL Off | S - Sale | $8.49 | -7,217 | 64.0K | -10% | -$61.2K |
| DM | 2025-03-20 | 2025-03-20 | STOK | Ticho Barry | Chief MEDICAL Off | A - Grant | $0.00 | +107.0K | 64.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-19 | S | D | 3,333 | $8.27 | 60,629 | D | — | — | (F3) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.06 to $8.95 per share, inclusive. |
| 2 | Common | Common Stock | 2025-03-18 | S | D | 3,884 | $8.67 | 63,962 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.11 to $8.925 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 3. |
| 3 | Derivative | Restricted Stock Units | 2025-03-20 | A | A | 43,000 | $0.00 | 43,000 | D | — · — to 2029-03-20 | 43,000 Common Stock | (F5) Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. (F6) The award vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the issuer through each vesting date. |
| 4 | Derivative | Employee Stock Option (Right to Buy) | 2025-03-20 | A | A | 64,000 | $0.00 | 64,000 | D | $8.33 · — to 2035-03-19 | 64,000 Common Stock | (F4) The option shall vest as to 1/48 of the total award on April 15, 2025, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. |